News

A multidisciplinary team of researchers from the London School of Hygiene & Tropical Medicine (LSHTM), have recently released results from a retrospective study showing that Glitazone, a type of drug used to treat diabetes may reduce the risk of developing Parkinson’s disease (PD).  The study, entitled, “…

New encouraging data on novel therapeutic drugs targeting components affected in several brain diseases linked to dementia have been recently presented at the Alzheimer’s Association International Conference 2015 (AAIC 2015) in Washington, D.C. The brain diseases considered included Parkinson’s disease, Alzheimer’s disease and Lewy Body dementia. All three conditions…

In a recent pilot study published in the journal Digital Health a team of researchers are testing new technologies for Parkinson’s disease (PD) which may influence clinical research in personal genetic testing to better diagnose and potentially treat PD. “These findings demonstrate that remote recruitment and conduct…

Amarantus BioScience Holdings, Inc., a biotechnology company focused on advancing therapeutic and diagnostic products for orphan and neurologic diseases, recently announced they have dosed the first patient in a Phase 2b clinical trial of flagship neurology pipeline drug eltoprazine, indicated as a potential treatment for Parkinson’s disease levodopa-induced dyskinesia (PD-LID).

In a new study entitled “Nuclear receptor Nurr1 agonists enhance its dual functions and improve behavioral deficits in an animal model of Parkinson’s disease” an international team of scientists discovered that anti-malaria drugs chloroquine and amodiaquine are potential therapeutics for Parkinson’s disease. The study was published in…

Plans for a new research venture is in the works in the North-West of England through the joint efforts of the Association for the Independence of Disabled People (AID) and medical researchers at Lancaster University. AID was founded by Mr. Paul and the Hon. Mrs. Ruth Adorian of Windermere, following Ruth’s own…

In a new study entitled “Dopaminergic Modulation of Decision Making and Subjective Well-Being”, published in the Journal of Neuroscience, researchers show that decisions on risk-taking may be influenced by a boost in the levels of the neurotransmitter dopamine. These findings are in line with previous reports that…